# Liminatus Pharma Inc. 股價週四收盤後飆升 79.34% 至 0.34 美元。

*biotech, business · news · 2026-05-21 · Benzinga*

## Key points

- Liminatus Pharma 週四宣布與 InnocsAI LLC 達成最終合併協議。
- InnocsAI 成員將獲得 16 億股 LIMN 股票，價格為每股 0.20 美元，另加或有權利。
- Liminatus 執行長 Chris Kim 控制的 Valetudo Therapeutics 是 InnocsAI 的成員。
- 此次合併帶來 IBC101，一款獲准在南韓進行第一/二期臨床試驗的 CAR-T 腫瘤候選藥物。

Liminatus Pharma Inc. (NASDAQ:LIMN) shares are trending on Friday. LIMN shares surged 79.34% to $0.34 after the bell on Thursday. The stock of the biopharmaceutical company had experienced an intraday drop of 1.16%, closing at $0.19, according to Benzinga Pro data. Liminatus announced a definitive merger agreement with Delaware-based limited liability company InnocsAI LLC on Thursday. According to the company announcement, InnocsAI members will receive 1.6 billion shares at $0.20 per share, plus contingent value rights representing 20% of net proceeds from future asset exits. What You Should Know Notably, Liminatus’s CEO Chris Kim controls Valetudo Therapeutics LLC, a member of InnocsAI. Liminatus Pharma has over 44.8 million shares outstanding. The deal brings a clinical-stage oncology portfolio, including IBC101, a CD19xCD22 bivalent CAR-T candidate authorized for a Phase 1/2a study in South Korea and preclinical solid tumor program INC101. The merger is subject to shareholder approval and SEC review, with a termination deadline of Dec. 31. Liminatus Pharma went public through a special purpose acquisition company (SPAC) merger with Iris Acquisition Corp in 2022. Trading Metrics, Technical Analysis Liminatus Pharma has a market capitalization of $8.43 million, a 52-week high of $33.66 and a 52-week low of $0.16. The Relative Strength Index (RSI) of LIMN stands at 42.16. The small-cap stock of the biotech has dropped 96.95% over the past 12 months. LIMN is currently trading close to its 52-week low. The stock's steep decline and weak positioning point to continued pressure, underscoring elevated risk and the need for clear recovery signals before investor confidence improves. Benzinga’s Edge Stock Rankings indicate that LIMN has a negative price trend across all time frames. Photo Courtesy: Alexandr Popel on Shutterstock.com

**Companies:** Liminatus Pharma Inc.
**Countries:** United States, South Korea

[Read the full story on Benzinga](https://www.benzinga.com/markets/equities/26/05/52708915/liminatus-pharma-is-trending-overnight-heres-why-limn-stock-surged-over-79-in-after-hours-session)

---

Canonical: https://newsio.io/zh-TW/n/28043669-d374-4f44-af05-db0cf7f31a9d/liminatus-pharma-inc-79-34-0-34-1-16
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works